BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2025 10:33:16 AM | Browse: 187 | Download: 708
 |
Received |
|
2024-08-11 14:45 |
 |
Peer-Review Started |
|
2024-08-11 14:45 |
 |
First Decision by Editorial Office Director |
|
2024-10-20 11:03 |
 |
Return for Revision |
|
2024-10-20 11:03 |
 |
Revised |
|
2024-11-03 05:48 |
 |
Publication Fee Transferred |
|
2024-11-09 01:21 |
 |
Second Decision by Editor |
|
2024-12-13 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2024-12-13 06:25 |
 |
Articles in Press |
|
2024-12-13 06:25 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-01-22 03:43 |
 |
Publish the Manuscript Online |
|
2025-02-14 10:33 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Penile metastasis from colon cancer with BRAFV600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Chen Wu, Hua-Xi Cheng, Qiu-Sheng Lan, He-Yang Xu, Yu-Jie Zeng, Wei Lai and Zhong-Hua Chu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81871981 |
| Natural Science Foundation of Guangdong Province |
2022A1515012348 and 2023A1515010457 |
|
| Corresponding Author |
Zhong-Hua Chu, MD, PhD, Professor, Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yan Jiang West Road, Guangzhou 510120, Guangdong Province, China. chuzhh@mail.sysu.edu.cn |
| Key Words |
Colon cancer; Penile metastasis; BRAFV600E mutation; Targeted therapy; Case report |
| Core Tip |
Despite the increasing incidence and prevalence of colorectal cancer among malignant tumors, penile metastasis originating from colorectal cancer remains a rare occurrence. The precise mechanism underlying penile metastasis of colorectal cancer remains elusive, and its specific treatment remains a subject of controversy, particularly in patients with BRAFV600E mutation, which often signifies an unfavorable prognosis. In our case, the treatment of BRAF/MEK-targeted therapy (dabrafenib and trametinib) plus cetuximab demonstrated promising outcomes, leading to tumor regression and prolonged survival, thereby offering valuable insights for the management of analogous cases. |
| Publish Date |
2025-02-14 10:33 |
| Citation |
Wu JC, Cheng HX, Lan QS, Xu HY, Zeng YJ, Lai W, Chu ZH. Penile metastasis from colon cancer with BRAFV600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report. World J Gastrointest Oncol 2025; 17(3): 100152 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i3/100152.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i3.100152 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.